Your Health, We Care
Ibrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Ibrutinib is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.
Ibrutinib is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
Ibrutinib is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
from FDA，2024.05
Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor that was first···【more】
Release date：2026-03-12Recommended：58
Ibrutinib (Imbruvica) is an oral Bruton's tyrosine kinase (BTK) inhibitor us···【more】
Release date：2026-03-12Recommended：48
Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of B···【more】
Release date：2026-03-12Recommended：56
Ibrutinib (Imbruvica) is a type of medication called a kinase inhibitor, used to···【more】
Release date：2026-03-12Recommended：44
Ibrutinib for the treatment of Chronic Lymphatic Leukemia【more】
Release date：2026-01-05Recommended：78
LuciusVersionofIbrutinib:DosageandAdministration,Indications,PrecautionsIndicati···【more】
Release date：2025-12-18Recommended：105
